Latest Boehringer Ingelheim Vetmedica Inc. Stories
ST. JOSEPH, Mo., Dec. 3, 2012 /PRNewswire/ -- Researchers at two universities will be studying equine pigeon fever (Corynebacterium pseudotuberculosis) as recipients of the 2012 Advancement of Equine Research Awards, sponsored by Boehringer Ingelheim Vetmedica, Inc. (BIVI). (Logo: http://photos.prnewswire.com/prnh/20120925/CG80722LOGO) Proposals by Roberta R. Pollock, Ph.D., professor of biology at Occidental College, and Allison J. Stewart, BVSc, professor of equine internal...
ST. JOSEPH, Mo., Sept. 25, 2012 /PRNewswire/ -- Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the addition of more than 75 positions to its U.S. sales force. The expanding animal health company plans to have all sales representatives and professional service veterinarians on board by early January 2013. The addition increases the entire BIVI field force to more than 350. (Logo: http://photos.prnewswire.com/prnh/20120925/CG80722LOGO) The increased sales force will help...
ST. JOSEPH, Mo., June 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Vetmedica, Inc. (BIVI) announces LeptoInfo.com has been updated to include new information on the spread of canine leptospirosis (lepto) in the United States and how pet owners can help lower the risks for their dogs. (Photo: http://photos.prnewswire.com/prnh/20120607/CG21089) The website will be available for pet owners on June 1, 2012 in time for late spring and warmer weather when exposure to lepto increases due...
ST. JOSEPH, Mo., April 30, 2012 /PRNewswire/ -- Public and private researchers studying Pigeon Fever (Corynebacterium pseudotuberculosis) are invited to submit proposals for the 2012 Equine Research Awards sponsored by Boehringer Ingelheim Vetmedica, Inc. (BIVI). (Logo: http://photos.prnewswire.com/prnh/20120430/CG97792LOGO) Proposals must address one or more specific criteria to be considered: Pathophysiology of Corynebacterium pseudotuberculosis and development of an equine...
ST. JOSEPH, Mo., June 20, 2011 /PRNewswire/ -- Dog lovers have big hearts. Now they can turn their passion for their pets into action by participating in a program that funds new research for canine heart disease - and perhaps win a vacation at the same time. In the online Million Heart Challenge, as soon as one million visitors click on the website, Boehringer Ingeleheim Vetmedica, Inc. (BIVI), will donate $15,000 to the American College of Internal Veterinary Medicine (ACVIM) to support...
INGELHEIM, Germany and ST. JOSEPH, Mo., Oct. 26 /PRNewswire/ -- Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities...
INGELHEIM, Germany and ST. JOSEPH, Mo., Sept. 21 /PRNewswire/ -- Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter. The deal, which is...
Vetmedin(R) proven to nearly double life expectancy of dogs with the most common heart condition ST. JOSEPH, Mo., Feb. 17 /PRNewswire/ -- A break-through drug to treat congestive heart failure (CHF) in dogs is now available in the United States. Boehringer Ingelheim Vetmedica, Inc. (BIVI) is the exclusive manufacturer of Vetmedin(R) (pimobendan), which is the first new drug approved by the FDA in over a decade to treat CHF in dogs. CHF is one of the most common heart problems in dogs,...
